BACKGROUND: Persistent MRSA bacteremia (PB) represents an important subset of Staphylococcus aureus infections and correlates with poor clinical outcomes. METHODS: We profiled relevant in vitro phenotypic and genotypic characteristics of MRSA isolates from 39 persons with bacteremia (21 had PB and 18 had resolving bacteremia [RB]). We also compared the intrinsic virulence and responsiveness to vancomycin of selected PB and RB strains in an experimental endocarditis model (IE). RESULTS: PB and RB isolates differed significantly with regard to several in vitro characteristics that are believed to impact endovascular infections. PB isolates exhibited significantly more resistance to the cationic defensin hNP-1, enhanced membrane fluidity, and substantially greater adhesion to fibronectin, fibrinogen, and endothelial cells. Genotypically, PB isolates had higher frequency of SCCmec II, CC30, and spa 16; and higher rates of agr type III, cap8, tst-1, and cna carriage. Finally, a prototypic PB strain was more resistant to vancomycin treatment in the infective endocarditis model than a RB comparator strain, despite equivalent virulence profiles. CONCLUSIONS: Our findings indicate that PB isolates may have specific virulence signatures that distinguish them from RB isolates. These data suggest that methods might be developed to identify patients at higher risk for PB in real-time, thereby optimizing the effectiveness of anti-MRSA therapeutic strategies.
BACKGROUND: Persistent MRSA bacteremia (PB) represents an important subset of Staphylococcus aureus infections and correlates with poor clinical outcomes. METHODS: We profiled relevant in vitro phenotypic and genotypic characteristics of MRSA isolates from 39 persons with bacteremia (21 had PB and 18 had resolving bacteremia [RB]). We also compared the intrinsic virulence and responsiveness to vancomycin of selected PB and RB strains in an experimental endocarditis model (IE). RESULTS: PB and RB isolates differed significantly with regard to several in vitro characteristics that are believed to impact endovascular infections. PB isolates exhibited significantly more resistance to the cationic defensin hNP-1, enhanced membrane fluidity, and substantially greater adhesion to fibronectin, fibrinogen, and endothelial cells. Genotypically, PB isolates had higher frequency of SCCmec II, CC30, and spa 16; and higher rates of agr type III, cap8, tst-1, and cna carriage. Finally, a prototypic PB strain was more resistant to vancomycin treatment in the infective endocarditis model than a RB comparator strain, despite equivalent virulence profiles. CONCLUSIONS: Our findings indicate that PB isolates may have specific virulence signatures that distinguish them from RB isolates. These data suggest that methods might be developed to identify patients at higher risk for PB in real-time, thereby optimizing the effectiveness of anti-MRSA therapeutic strategies.
Authors: Vance G Fowler; Charlotte L Nelson; Lauren M McIntyre; Barry N Kreiswirth; Alastair Monk; Gordon L Archer; Jerome Federspiel; Steven Naidich; Brian Remortel; Thomas Rude; Pamela Brown; L Barth Reller; G Ralph Corey; Steven R Gill Journal: J Infect Dis Date: 2007-07-20 Impact factor: 5.226
Authors: Binh An Diep; Heather A Carleton; Richard F Chang; George F Sensabaugh; Francoise Perdreau-Remington Journal: J Infect Dis Date: 2006-04-21 Impact factor: 5.226
Authors: Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth Journal: Clin Infect Dis Date: 2011-12-20 Impact factor: 9.079
Authors: Steven K Lower; Ruchirej Yongsunthon; Nadia N Casillas-Ituarte; Eric S Taylor; Alex C DiBartola; Brian H Lower; Terrance J Beveridge; Andrew W Buck; Vance G Fowler Journal: Biophys J Date: 2010-11-03 Impact factor: 4.033
Authors: Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: R San-Juan; D Pérez-Montarelo; E Viedma; A Lalueza; J Fortún; E Loza; M Pujol; C Ardanuy; I Morales; M de Cueto; E Resino-Foz; M A Morales-Cartagena; M Fernández-Ruiz; A Rico; M P Romero; M Fernández de Mera; F López-Medrano; M Á Orellana; J M Aguado; F Chaves Journal: Eur J Clin Microbiol Infect Dis Date: 2017-05-05 Impact factor: 3.267
Authors: Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong Journal: J Antimicrob Chemother Date: 2015-01-05 Impact factor: 5.790
Authors: Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas Journal: J Infect Dis Date: 2010-01-15 Impact factor: 5.226
Authors: Andrew W Buck; Vance G Fowler; Ruchirej Yongsunthon; Jie Liu; Alex C DiBartola; Yok-Ai Que; Philippe Moreillon; Steven K Lower Journal: Langmuir Date: 2010-07-06 Impact factor: 3.882